Neuronetics (STIM) EVP Macan sells 16,005 shares to cover RSU tax

Rhea-AI Filing Summary

Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 16,005 shares of common stock at a weighted average price of $1.34 per share. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding upon vesting of a performance restricted stock unit award, and he continues to hold 897,270 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACAN WILLIAM ANDREW

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO and CS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		S		16,005(1)	D	$1.34(2)	897,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a performance restricted stock unit award.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.48 to $1.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Patrick Devine, as Attorney-in-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neuronetics (STIM) report for William Andrew Macan?

William Andrew Macan reported selling 16,005 Neuronetics common shares. The filing states these were non-discretionary sales to satisfy his tax withholding obligations triggered by vesting of a performance restricted stock unit award, rather than a discretionary decision to reduce his investment position.

At what price were William Andrew Macan’s Neuronetics (STIM) shares sold?

The reported weighted average sale price was $1.34 per Neuronetics share. A footnote explains the shares were sold in multiple transactions at prices ranging from $1.20 to $1.48, with detailed trade breakdowns available to regulators, the company, or stockholders upon request.

How many Neuronetics (STIM) shares does William Andrew Macan hold after this Form 4 sale?

After the reported transaction, William Andrew Macan directly holds 897,270 shares of Neuronetics common stock. This context shows the 16,005 shares sold for tax withholding represent a relatively small portion of his total reported direct ownership in the company.

Why were William Andrew Macan’s Neuronetics (STIM) shares sold according to the Form 4?

The Form 4 states the sales were non-discretionary to satisfy tax withholding obligations. These obligations arose when a portion of a performance restricted stock unit award vested, meaning the shares were sold automatically to cover taxes rather than as a voluntary portfolio adjustment.

What role does William Andrew Macan hold at Neuronetics (STIM)?

William Andrew Macan is identified as an officer of Neuronetics, serving as Executive Vice President, Chief Legal Officer, and Corporate Secretary. His Form 4 filing reflects transactions in company common stock related to equity compensation and associated tax withholding requirements.